Bioxytran, Inc (BIXT) Stock Price & Analysis
Bioxytran, Inc (BIXT) rose 0.08% to USD 0.02 as of July 25, 2026 at 06:09 UTC, according to Nexqual real-time market data.
BIXT last closed at USD 0.02; the session ranged USD 0.02–0.02 on volume of 43,440 shares. Market capitalization is $2.72M, with a 52-week range of USD 0.02–0.1 (OQB). Source: Nexqual, July 25, 2026 at 06:09 UTC.
Key Statistics (as of July 25, 2026 at 06:09 UTC)
| Price | USD 0.02 |
|---|---|
| Change | ▲ 0.08% (up) |
| Previous Close | USD 0.02 |
| Open | USD 0.02 |
| Day Range | USD 0.02 – 0.02 |
| 52-Week Range | USD 0.02 – 0.1 |
| Volume | 43,440 shares |
| Market Cap | $2.72M |
| Exchange | OQB |
Technical Analysis (BIXT)
Nexqual's technical model rates BIXT "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of July 25, 2026 at 06:09 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.66 (neutral) |
| vs SMA50 | Below (USD 0.03) |
| MACD | -0 (negative) |
Analyst Ratings (BIXT)
Wall Street analysts rate BIXT "None", per Nexqual as of July 25, 2026 at 06:09 UTC.
| Consensus Rating | None |
|---|
Earnings (BIXT)
Source: Nexqual, July 25, 2026 at 06:09 UTC.
Financials & Fundamentals (BIXT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.09 |
| Total Cash | $463,047 |
| Total Debt | $1.21M |
| Free Cash Flow | $1.49M |
Source: Nexqual, July 25, 2026 at 06:09 UTC.
Financial Health Score (BIXT)
Nexqual rates Bioxytran, Inc's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:09 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $463K cash vs $1M debt |
| Cash Flow | Weak — Operating cash flow -$598K |
| Efficiency | Mixed — No data |
Ownership (BIXT)
| Insider Ownership | +0.62% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 114.20M |
| Float | 113.49M |
Source: Nexqual, July 25, 2026 at 06:09 UTC.
Leadership (BIXT)
Bioxytran, Inc is led by David Platt (age 72), Chairman, CEO, President & Secretary, per Nexqual as of July 25, 2026 at 06:09 UTC.
| Chairman, CEO, President & Secretary | David Platt (age 72) |
|---|---|
| CFO & Treasurer | Ola Soderquist C.M.A., C.P.A., CM&AA (age 63) |
From Bioxytran, Inc's Latest SEC 10-K Filing (filed 2026-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- During viral infections galectins are upregulated and downregulated based on the type of virus.   To our knowledge, Pharmalectin, Inc. is the only company planning to develop a viable end-to-end solution for Covid-19.
- We will rely on a combination of patent applications, patent, trade secrets, proprietary know-how and trademarks to protect our proprietary rights.
- To produce BXT-25, we will take red blood cells (RBCs) from camel sources, isolate hemoglobin from the RBCs and, by applying our proprietary co-polymer chemistry, stabilize and modify the hemoglobin.
- Our technology involves the development of hemoglobin-based oxygen carriers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BIOAF | BIOASIS TECHNOLOGIES INC | USD 0 | ▲ 0% |
| AOXG | Aoxing Pharmaceutical Company, | USD 0 | ▲ 0% |
| EAWD | Energy and Water Development Co | USD 0 | ▲ 0% |
| BVAXF | BioVaxys Technology Corp. | USD 0.12 | ▲ 9.09% |
| GSAC | GelStat Corp. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:09 UTC. This page is informational and not investment advice.